Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, has been notified by Sanofi Pasteur Canada, which manufactures the bladder cancer treatment ImmuCyst and licenses it to Alliance for distribution in the UK and Ireland, that Sanofi Pasteur has decided to temporarily suspend manufacturing of ImmuCyst to address certain production issues that have arisen. Sanofi Pasteur has advised that its preliminary estimate is to resume supply of ImmuCyst in late 2013. ImmuCyst currently generates around £2m gross margin per annum for Alliance and accordingly the Board of Alliance expects that the results for the year end 31 December 2012 could be adversely affected by approximately £1m. Alliance is exploring ways to mitigate the impact
Good Morning Inmates. I am here to say Good Bye, I hate good byes’ but enough is enough ones must know ones limits THANK YOU APH and good bye; you know I have been faithful and you have been wonderful to me because of you I could now and decide to have my retirement a little earlier, 2 steps forward. Good Bye all I wish you all good lucks and good health, be faithful like me and soon you’ll able to do like me – if this is what you wished
In May 2010 an astonishing revelation came to light. Scancell was to trial a vaccine that, in an earlier version, had already cured two girls of bone cancer! The elder of the two wished to remain anonymous but Amy Dickenson, by now 20 years old and pregnant with her second baby, was only too pleased to bear witness to the miracle cure which saved her life. As an eight year old, Amy was entered into a trial of the early version of Scancell's vaccine, configured at that time to treat bone cancer. In Amy's case an advanced stage of this cancer had developed in her left leg. Despite gruelling surgery and chemotherapy, the disease persisted and spread to her lungs. Amy was not expected to survive, yet she was found to be cured following the treatment. Professor Kathy Pritchard Jones, who led the trial with both girls, at the Royal Marsden Hospital in London, said: “I believe the vaccine played a vital role in their recovery. It is incredibly promising that patients with this almost incurable disease have gone on to live normal lives.” Scancell is currently engaged in new clinical trials with the latest version of the vaccine reconfigured to treat malignant melanoma, the most aggressive form of skin cancer. Designated SCIB1, this will be the first vaccine Scancell has designed for commercial use. A second vaccine to treat lung cancer is also in development. Professor Lindy Durrant, Joint CEO of Scancell commented: "In the short term, this could cure some patients with the disease, and in the long term it could be used to prevent people developing it in the first place." Professor Karol Sikora, a leading cancer expert, added: "This is a very clever vaccine and I believe it will increase the cure rate for patients in the future."
Brewin Dolphin downgraded Alliance Pharma (APH) from "add" to "hold" with a reduced target price of 33p, from 31p. The pharmaceutical company missed the broker's pre-tax profit target for the 2011 financial year by 4%. Brewin notes a particularly poor performance from the group's Deltacortril anti-inflammatory drug, with sales 13% behind target at 4.7 million pounds. On a more positive note, the broker said that its high exposure to the UK and prescription market should make the firm more resilient against austerity measures in Europe. The shares inched down 0.125p to 28.625p.
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that its wholly owned subsidiary Alliance Pharmaceuticals Limited has acquired the brands QuinodermTM and CeanelTM from Ferndale Pharmaceuticals Limited for £1.5m cash consideration.
Quinoderm is a well-established medication for the treatment of acne and Ceanel is a shampoo treatment for scalp psoriasis. For the twelve months ended 30 September 2011 the acquired products had total sales of approximately £0.6 million.
Alliance is funding the acquisition by drawing a loan from the £20m Revolving Credit Facility ("RCF") put in place in November 2010 to fund acquisitions. This brings the current utilisation of the RCF to £6.5m.
Commenting on the acquisition, John Dawson, Alliance Pharma's Chief Executive, said: "We are delighted to announce this acquisition, which extends our Dermatology portfolio. Quinoderm complements our existing product Rizuderm (isotretinoin), a treatment for severe acne acquired in September this year.
"Today's acquisition, which represents our third transaction this year, is expected to be earnings enhancing in 2012. We continue to evaluate further opportunities to broaden our product portfolio."
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.